|
1
|
Vilmar AC and Sorensen JB: Customising
chemotherapy in advanced nonsmall cell lung cancer: Daily practice
and perspectives. Eur Respir Rev. 20:45–52. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barclay AN, Clark MJ and McCaughan GW:
Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the
immunoglobulin superfamily with a light-chain-like structure.
Biochem Soc Symp. 51:149–157. 1986.PubMed/NCBI
|
|
3
|
Moreaux J, Hose D, Reme T, Jourdan E,
Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, et al:
CD200 is a new prognostic factor in multiple myeloma. Blood.
108:4194–4197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wright GJ, Cherwinski H, Foster-Cuevas M,
Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D,
McClanahan T, et al: Characterization of the CD200 receptor family
in mice and humans and their interactions with CD200. J Immunol.
171:3034–3046. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tonks A, Hills R, White P, Rosie B, Mills
KI, Burnett AK and Darley RL: CD200 as a prognostic factor in acute
myeloid leukaemia. Leukemia. 21:566–568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moreaux J, Veyrune JL, Reme T, De Vos J
and Klein B: CD200: A putative therapeutic target in cancer.
Biochem Biophys Res Commun. 366:117–122. 2008. View Article : Google Scholar
|
|
7
|
Liu JQ, Talebian F, Wu L, Liu Z, Li MS,
Zhu J, Markowitz J, Carson WE III, Basu S and Bai XF: A critical
role for CD200R signaling in limiting the growth and metastasis of
CD200+ melanoma. J Immunol. 197:1489–1497. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karp X and Ambros V: Developmental
biology. Encountering microRNAs in cell fate signaling. Science.
310:1288–1289. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weiler J, Hunziker J and Hall J:
Anti-miRNA oligonucleotides (AMOs): Ammunition to target miRNAs
implicated in human disease? Gene Ther. 13:496–502. 2006.
View Article : Google Scholar
|
|
10
|
Latronico MV, Catalucci D and Condorelli
G: Emerging role of microRNAs in cardiovascular biology. Circ Res.
101:1225–1236. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Y, Fu LL, Wen X, Liu B, Huang J, Wang
JH and Wei YQ: Oncogenic and tumor suppressive roles of microRNAs
in apoptosis and autophagy. Apoptosis. 19:1177–1189. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sonkoly E, Wei T, Janson PC, Sääf A,
Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, Homey B,
Scheynius A, et al: MicroRNAs: Novel regulators involved in the
pathogenesis of psoriasis? PLoS One. 2:e6102007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cheng L, Gao S, Song X, Dong W, Zhou H,
Zhao L and Jia L: Comprehensive N-glycan profiles of hepatocellular
carcinoma reveal association of fucosylation with tumor progression
and regulation of FUT8 by microRNAs. Oncotarget. 7:61199–61214.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hansen T, Olsen L, Lindow M, Jakobsen KD,
Ullum H, Jonsson E, Andreassen OA, Djurovic S, Melle I, Agartz I,
et al: Brain expressed microRNAs implicated in schizophrenia
etiology. PLoS One. 2:e8732007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li M, Zhang S, Wu N, Wu L, Wang C and Lin
Y: Overexpression of miR-499-5p inhibits non-small cell lung cancer
proliferation and metastasis by targeting VAV3. Sci Rep.
6:231002016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang XH, Wang FR, Tang YF, Zou HZ and Zhao
YQ: Association of miR-149C>T and miR-499A>G polymorphisms
with the risk of hepatocellular carcinoma in the Chinese
population. Genet Mol Res. 13:5048–5054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bohling SD, Davis E, Thompson K, Kussick
SJ and Love J: Flow cytometric analysis of CD200 expression by
pulmonary small cell carcinoma. Cytometry B Clin Cytom. 90:493–498.
2016. View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishibashi M, Neri S, Hashimoto H,
Miyashita T, Yoshida T, Nakamura Y, Udagawa H, Kirita K, Matsumoto
S, Umemura S, et al: CD200-positive cancer associated fibroblasts
augment the sensitivity of epidermal growth factor receptor
mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase
inhibitors. Sci Rep. 7:466622017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li L, Pan X, Li Z, Bai P, Jin H, Wang T,
Song C, Zhang L and Gao L: Association between polymorphisms in the
promoter region of miR-143/145 and risk of colorectal cancer. Hum
Immunol. 74:993–997. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Saunders MA, Liang H and Li WH: Human
polymorphism at microRNAs and microRNA target sites. Proc Natl Acad
Sci USA. 104:3300–3305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu HY, Wang ZY, Chen JF, Wang TY, Wang LL,
Tang LL, Lin XY, Zhang CW and Chen BC: Association between
ankylosing spondylitis and the miR-146a and miR-499 polymorphisms.
PLoS One. 10:e01220552015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oner T, Yenmis G, Tombulturk K, Cam C,
Kucuk OS, Yakicier MC, Dizman D and Sultuybek GK: Association of
Pre-miRNA-499 rs3746444 and Pre-miRNA-146a rs2910164 polymorphisms
and susceptibility to behcet's disease. Genet Test Mol Biomarkers.
19:424–430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen W, Shao D, Gu H, Gong J and Zhang J:
Hsa-mir-499 rs3746444 T/C polymorphism is associated with increased
risk of coronary artery disease in a Chinese population. Acta
Cardiol Sin. 33:34–40. 2017.PubMed/NCBI
|
|
28
|
Toraih EA, Ismail NM, Toraih AA, Hussein
MH and Fawzy MS: Precursor miR-499a variant but not miR-196a2 is
associated with rheumatoid arthritis susceptibility in an Egyptian
population. Mol Diagn Ther. 20:279–295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zou HZ and Zhao YQ: Positive association
between miR-499A>G and hepatocellular carcinoma risk in a
Chinese population. Asian Pac J Cancer Prev. 14:1769–1772. 2013.
View Article : Google Scholar
|
|
30
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wright GJ, Jones M, Puklavec MJ, Brown MH
and Barclay AN: The unusual distribution of the neuronal/lymphoid
cell surface CD200 (OX2) glycoprotein is conserved in humans.
Immunology. 102:173–179. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Koning N, Swaab DF, Hoek RM and Huitinga
I: Distribution of the immune inhibitory molecules CD200 and CD200R
in the normal central nervous system and multiple sclerosis lesions
suggests neuron-glia and glia-glia interactions. J Neuropathol Exp
Neurol. 68:159–167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jenmalm MC, Cherwinski H, Bowman EP,
Phillips JH and Sedgwick JD: Regulation of myeloid cell function
through the CD200 receptor. J Immunol. 176:191–199. 2006.
View Article : Google Scholar
|
|
34
|
Zhang S, Cherwinski H, Sedgwick JD and
Phillips JH: Molecular mechanisms of CD200 inhibition of mast cell
activation. J Immunol. 173:6786–6793. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Minas K and Liversidge J: Is the
CD200/CD200 receptor interaction more than just a myeloid cell
inhibitory signal? Crit Rev Immunol. 26:213–230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Olteanu H, Harrington AM, Hari P and Kroft
SH: CD200 expression in plasma cell myeloma. Br J Haematol.
153:408–411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pojero F, Casuccio A, Parrino MF,
Cardinale G, Colonna Romano G, Caruso C and Gervasi F: Old and new
immunophenotypic markers in multiple myeloma for discrimination of
responding and relapsing patients: The importance of 'normal'
residual plasma cell analysis. Cytometry B Clin Cytom. 88:165–182.
2015. View Article : Google Scholar
|
|
38
|
Conticello C, Giuffrida R, Parrinello N,
Buccheri S, Adamo L, Sciuto MR, Colarossi C, Aiello E, Chiarenza A,
Romano A, et al: CD200 expression in patients with multiple
Myeloma: Another piece of the puzzle. Leuk Res. 37:1616–1621. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cannizzo E, Bellio E, Sohani AR,
Hasserjian RP, Ferry JA, Dorn ME, Sadowski C, Bucci JJ, Carulli G
and Preffer F: Multiparameter immunophenotyping by flow cytometry
in multiple myeloma: The diagnostic utility of defining ranges of
normal antigenic expression in comparison to histology. Cytometry B
Clin Cytom. 78:231–238. 2010.PubMed/NCBI
|
|
40
|
Alapat D, Coviello-Malle J, Owens R, Qu P,
Barlogie B, Shaughnessy JD and Lorsbach RB: Diagnostic usefulness
and prognostic impact of CD200 expression in lymphoid malignancies
and plasma cell myeloma. Am J Clin Pathol. 137:93–100. 2012.
View Article : Google Scholar
|
|
41
|
Coustan-Smith E, Song G, Clark C, Key L,
Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH, et al: New
markers for minimal residual disease detection in acute
lymphoblastic leukemia. Blood. 117:6267–6276. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kapoor A, Kumar N, Narayan S, Nirban RK,
Maharia S, Beniwal SK, Jakhar SL and Kumar HS: 101pda prospective
randomized open label phase III study of geftinib versus docetaxel
as second or third line therapy in patients with advanced non small
cell lung cancer in asian indians. Ann Oncol. 26(Suppl 1): S29–S44.
2015.
|
|
43
|
Siva A, Xin H, Qin F, Oltean D, Bowdish KS
and Kretz-Rommel A: Immune modulation by melanoma and ovarian tumor
cells through expression of the immunosuppressive molecule CD200.
Cancer Immunol Immunother. 57:987–996. 2008. View Article : Google Scholar
|
|
44
|
Colmont CS, Benketah A, Reed SH, Hawk NV,
Telford WG, Ohyama M, Udey MC, Yee CL, Vogel JC and Patel GK:
CD200-expressing human basal cell carcinoma cells initiate tumor
growth. Proc Natl Acad Sci USA. 110:1434–1439. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stumpfova M, Ratner D, Desciak EB, Eliezri
YD and Owens DM: The immunosuppressive surface ligand CD200
augments the metastatic capacity of squamous cell carcinoma. Cancer
Res. 70:2962–2972. 2010. View Article : Google Scholar : PubMed/NCBI
|
